Really interesting new gene (RING) finger proteins represent a large protein family in the human genome, and play crucial roles in physiological activities and cancer development. The biological functions of some RING finger proteins remain unknown. Here, we described the biological activity of a novel, human Golgi-localized RING finger protein 121 (RNF121), the function of which is, thus far, unknown. Unlike the endoplasmic reticulum-localized RNF121 in Caenorhabditis elegans, human RNF121 is predominantly localized to the Golgi apparatus. RNF121 knockdown inhibited cell growth and induced apoptosis, which was accompanied by caspase-3 activation and the cleavage of poly (adenosine diphosphate-ribose) polymerase. Z-VAD-FMK, a pan-caspase inhibitor, inhibited the RNF121 knockdowninduced apoptosis. Over-expression of wild-type RNF121, but not the RING domain mutants of RNF121, decreased RNF121 knockdown-induced apoptosis, indicating that the RING domain is required for RNF121-regulated apoptosis. Moreover, RNF121 knockdown enhanced etoposide-induced apoptosis. This is the first study to demonstrate that RNF121 is a novel regulator of apoptosis and provides a new potential target for cancer therapy.
Introduction
RING (really interesting new gene) finger protein was first described using a special amino acid sequence and structure 20 years ago [1] . Currently, RING finger proteins have been proven to play numerous essential roles in physiology and pathophysiology [2] . In cancer development, RING finger proteins can act as oncogenes or tumor suppressors. They can regulate different aspects of cancer cells, such as cell cycle [3] , signal transduction [4] , genomic integrity [5] , hypoxia [6] , and metastasis [7] . Apoptosis is the process of programmed cell death and is considered a crucial factor in the maintenance of cell homeostasis [8] . Malfunction of the cellular apoptosis machine is a common reason for cancer initiation and progression [9] . The apoptosis-based method is very promising for cancer therapy [10] .
Of over 600 human RING domain genes, only a small number of functions have been studied [1] . The biological function of RING domain proteins remains largely unknown. The cDNA of RING finger protein 121 (RNF121) was first identified in a cDNA clone analysis of the Mammalian Gene Collection Program [11] . An epidemiological study has implicated the involvement of RNF121 in breast cancer development [12] . A study has demonstrated that RNF121 was an endoplasmic reticulum (ER)-localized protein and was involved in ER stress in Caenorhabditis elegans [13] . Here, we provided the evidence that human RNF121 was a Golgi apparatus-localized protein. RNF121 knockdown did not lead to a significant difference in ER stress compared with control cells. Further studies indicated that RNF121 was involved in cell growth and apoptosis. Cell lines and cell transfection HeLa cells were from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China), and U2OS and MCF-7 cells were from the American Type Culture Collection (Manassas, USA). All cell lines were maintained in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, USA) supplemented with 10% fetal bovine serum (HyClone, Logan, USA) and cultured in a 378C, 5% CO 2 humidified atmosphere. Cell transfection was conducted using Lipofectamine 2000 (Invitrogen) following the manufacturer's instructions.
Materials and Methods

Antibodies and reagents
Reverse transcription-polymerase chain reaction, plasmid construction, and siRNA design To detect the expression profiles of RNF121 in the human tissues, reverse transcription-polymerase chain reaction (RT-PCR) was conducted using 5 0 -GGCATGCCTACCAAACAT CT-3 0 and 5 0 -GGCCCAGGATGTAGTTGATG-3 0 primers. The coding sequence (CDS) of RNF121 (NM_018320) cDNA was amplified from HeLa cell cDNA library by RT-PCR and cloned into pcDNA3.1, pEGFP-C1, and pTagRFP-N vectors (Fig. 1E) . Mutation (RNF121 C229AC259A ) and deletion (RNF121 ) constructs were developed based on pcDNA3.1-RNF121. All plasmids were confirmed by DNA sequencing. For the knockdown of RNF121, three short interfering RNAs were chemically synthesized (siRNA, Gene Pharma Co., Shanghai, China). The sequences were as follows: siRNF121-1 (gcagactacatggcatcta), siRNF121-2 (ggttcctgct aatctataa), and siRNF121-3 (gtcatcattggtgtagtcc).
Light and confocal microscopy HeLa, U2OS, and MCF-7 cells were plated on glass coverslips and transfected with either siRNA control (uucuccgaacgugucacgu) or siRNF121 for 48 h, and the cell morphology was observed and photographed under light microscopy. To observe RNF121 localization, HeLa and U2OS cells were cultured in confocal dishes and transfected with either siRNA control or siRNF121 for 48 h, fixed with 4% paraformaldehyde, and observed using a Leica SP5 confocal system. Nuclei were stained with Hoechst 33258 (Sigma Aldrich) before microscopy observation.
Cell viability assay
The cell survival assay was performed using the CellTiter 96 w AQ ueous Non-Radioactive Cell Proliferation Assay according to the manufacturer's instructions. Briefly, HeLa, U2OS, and MCF-7 cells were plated in 96-well plates in triplicate. Cells were cultured overnight and then transfected with either siRNA control or siRNF121. Forty-eight hours later, 10 ml/ well combined 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxyme thoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)/phen azine methosulfate solution was added. After 1 h at 378C in a humidified, 5% CO 2 atmosphere, the absorbance at 490 nm was recorded using an enzyme-linked imunosorbent assay plate reader. The viability of the siRNA transfected cells was normalized to the control.
Western blot analysis
Cells were collected and disrupted in lysis buffer [50 mM Tris ( pH 7.4), 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), sodium orthovanadate, sodium fluoride, ethylenediaminetetraacetic acid] containing protease inhibitors (Complete Protease Inhibitor Cocktail; Roche Diagnostics, Indianapolis, USA). Total cell extracts were quantified by bicinchoninic acid assay, resolved by SDS-polyacrylamide gel electrophoresis, transferred to nitrocellulose membranes, and probed using the indicated antibodies. Protein bands were visualized using the DyLight 800 conjugated secondary anti-rabbit antibody or DyLight 680 conjugated secondary anti-mouse antibody, and the infrared fluorescence image was obtained using an Odyssey infrared imaging system (LI-COR Biosciences, St Lincoln, USA). 
Flow cytometry
Results
Bioinformatics analysis and expression profile of human RNF121 Figure 1A depicts a schematic map of the RNF121 sequence. The human RNF121 gene is located in a 69 kb segment on chromosome 11q13.4 and comprises nine exons and eight introns. The mature mRNA of RNF121 is 2623 bp long. The open reading frame encodes a predicted 327 amino acids with a molecular weight of 37.86 kDa. The predicted transmembrane (TM) domains are colored blue. The RNF121 regulates apoptosis RING domain sequence showed that RNF121 is a C3H2C3-type RING finger. Protein sequence analysis revealed that RNF121 is well conserved (Fig. 1B) . Every homologous gene contains a RING-H2 finger (C3H2C3-type RING finger) with high protein sequence identities (Fig. 1B) . TM analysis (http://www.cbs.dtu.dk/services/TMHMM-2.0/) suggested that the RNF121 protein contains five conserved TM domains and that the RING finger domain faces the cytosol (Fig. 1C) . RT-PCR demonstrated that RNF121 mRNA is expressed in a variety of normal human tissues, including the kidney, heart, lung, brain, liver, pancreas, prostate, skeletal muscle, thymus, placenta, spleen, and peripheral blood lymphocytes (Fig. 1D) .
Human RNF121 is predominantly located in Golgi apparatus In C. elegans, RNF121 is located in the ER [13] . Interestingly, we found that the human RNF121 did not colocalize with ER-DsRed, an ER marker, in HeLa cells ( Fig. 2A) . Rather, it was localized predominantly in the Golgi apparatus in HeLa and U2OS cells (Fig. 2B,C) . In HeLa cells, the N-terminal green fluorescent protein (GFP)-tagged RNF121 colocalized entirely with the C-terminal pTagRFP (tRFP)-tagged RNF121 (Fig. 2D) , which suggests that the location of RNF121 in the Golgi apparatus is not due to the different terminal tags. We tried to use RNF121 antibody to test the endogenous location of RNF121, but the RNF121 Knockdown of human RNF121 inhibited cell growth through apoptosis To investigate the biological activities of RNF121 through siRNA interference, we tested three candidate siRNAs against RNF121 (siRNF121-1, -2, and -3). As shown in Fig. 3A , the levels of RNF121 protein were significantly decreased in HeLa cells treated with siRNF121-1. By contrast, siRNF121-2, siRNF121-3, and the siRNA control exerted no such effects. Therefore, we selected siRNF121-1 for the subsequent experiments, renaming it as siRNF121.
We next evaluated the association of siRNF121 treatment with cell viability. HeLa, U2OS, and MCF-7 cell lines transfected with siRNA control or siRNF121 were assayed. Fortyeight hours after transfection, we observed morphological changes in siRNF121-treated cells as compared with siRNA control-transfected cells under light microscopy (Fig. 3B) . The changes in morphology of the siRNF121-treated cells included marked shrinkage, rounding, bubbling, and detachment from the culture dish. We further analyzed the viability of the cells treated by either siRNA control or siRNF121 using the MTS assay. As shown in Fig. 3C , it is clear that RNF121 knockdown induced significant growth inhibition in the siRNF121-treated cells as compared with those treated 
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with the siRNA control. The data suggested the anti-prolife rative effect of siRNF121 in HeLa, U2OS, and MCF-7 cells (Fig. 3C) .
As apoptosis is a factor that regulates cell death, we then detected the exposure of phosphatidylserine (PS), which is a key biochemical hallmark of apoptosis. The exposure of PS on the surface of apoptotic cells can be identified easily by flow cytometry using fluorescence-labeled Annexin V, which specifically binds PS. Using this assay, we detected the percentage of apoptosis through FITC-Annexin V staining after transfection with siRNF121 or siRNA control. Plasma membrane integrity was simultaneously assessed by PI exclusion staining using two-color fluorescence-activated cell sorting analysis. A representative result of HeLa cell flow cytometry shows that siRNF121 resulted in an increase in the number of apoptotic cells that was more than two times that of the siRNA control-treated cells (Fig. 3D, top) . Consistent with this finding, RNF121 knockdown increased the cleavage of caspase-3 and PARP, which is a caspase-3 substrate (Fig. 3E, lane 2 vs. lane 1) . These results suggested that the inhibition of RNF121 expression induced growth inhibition through apoptosis.
To determine whether apoptosis enhanced by RNF121 was caspase-dependent, HeLa cells transfected with either siRNA control or siRNF121 were treated with 40 mM Z-VAD-FMK, a cell-permeating, irreversible pan-caspase inhibitor that inhibits the activity of caspase family proteases and blocks apoptosis [10] . A subsequent FITC-Annexin V/ PI assay showed that the Z-VAD-FMK treatment almost completely inhibited the increased apoptosis induced by siRNF121 (Fig. 3D, middle) . In addition, Z-VAD-FMK inhibited the cleavage of caspase-3 and PARP (Fig. 3E, lane  4 vs. lane 2) . Collectively, these data indicated that the knockdown of RNF121 expression induced apoptosis at least in part via caspase signaling.
In C. elegans, RNF121 inactivation or knockdown caused ER stress [13] . From previous studies, we found that RNF121 knockdown in HeLa cells led to no difference in the expression level of GRP78 protein (an ER stress marker) with or without the ER stress inducer DTT [14] ( Supplementary  Fig. S1 ). However, siRNF121 alone or DTT treatment enhanced the cleavage of PARP in siRNF121-transfected cells ( Supplementary Fig. S1, lanes 2, 4) , indicating that the inhibition of RNF121 expression might be involved in PARP inactivation. These results, together with mentioned above, indicate that human RNF121 has different cellular location and function comparing to its homolog protein in C. elegans.
Knockdown of human RNF121 enhanced cell apoptosis induced by VP-16
Etoposide (VP-16) is a commonly used agent in cancer chemotherapy that promotes cancer cell apoptosis [15] . We found that RNF121 knockdown significantly enhanced VP-16-induced apoptosis when compared with the siRNA control (Fig. 3D, bottom) . This is a further indication of the importance of siRNF121 in apoptosis and cancer therapy. In contrast, over-expression of wild-type RNF121 or RNF121 mutants failed to exert significant effects on apoptosis with or without VP-16 treatment, although wild-type RNF121 showed a weak anti-apoptosis effect (Supplementary Fig. S2 ).
Wild-type RNF121 could rescue cell apoptosis induced by RNF121 knockdown RNF121 was characterized by a highly conserved RING domain (Fig. 1B) , which has been described as an E3 ligase module [13] . The role of the RING domain is dependent on conserved amino acids such as C3H2C3 amino acid residues [1, 2] . Deletion or mutation of amino acid residue in C3H 2C3 leads to inactivation of RING domain [1, 2, 13] . It is likely that RNF121 regulates apoptosis through its RING domain. To evaluate this hypothesis, HeLa cells were cotransfected with siRNF121 and the indicated plasmids, i.e. the pcDNA3.1 vector, wild-type RNF121, RNF121 , and RNF121 C229AC259A . The results illustrated in Fig. 4 clearly showed that only the wild-type RNF121 decreased the apoptosis induced by siRNF121, whereas RNF121 1-225 and RNF121 C229AC259A had little effect on the siRNF121-induced apoptosis. These results suggest that the RING domain is required for RNF121-regulated apoptosis.
Discussion
In this report, we proved that human RNF121 is a novel Golgi apparatus-localized protein that could bear different subcellular location and function to its homolog protein in C. elegans, despite they share a highly conserved RING domain. Knockdown of RNF121 induced cell death through apoptosis and enhanced cell death induced by VP-16, while over-expression of RNF121 showed weak anti-apoptosis effect. The RING domain mutated (RNF121 C229AC259A ) or truncated RNF121 (RNF121 1-225 ) could not alleviate the cell death induced by knockdown of RNF121. RNF121 C229AC259A and RNF121 1-225 also showed no anti-apoptosis effect when over-expressed.
Human RNF121 showed different subcellular locations with C. elegans, which may have resulted from the divergent evolutionary process of this gene. The expression level of RNF121 (CG15814) could be modulated during coevolution of Drosophila species [16] , which implies that RNF121 may play an important role during the evolution of species. As An epidemiology study implied that human RNF121 might be linked to cancer susceptibility [12] . But how RNF121 relates to cancer development still remains unknown. Our results suggest that human RNF121 has anti-apoptosis effect in cancer cells, and sheds new light on the relation between RNF121 and cancer. RING finger proteins have been proved to play crucial roles in cancer development [2] . RNF7 can protect cancer cells from apoptosis, dependent on its RING domain [17] . RNF2 protects cancer cells from apoptosis as an E3 ligase that targets p53 for degradation by proteasome [18] . Knockdown of these RING finger proteins induced cell apoptosis [17, 18] , as RNF121 did. It is possible that RNF121 regulates apoptosis through targeting apoptosis-related molecules for degradation. On the other hand, RNF2 and RNF7 did not have apparent Golgi-specific location [18, 19] . Golgilocated RING finger proteins are usually involved in the Golgi-related transport, such as Neurodap1 [20] and MARCH2
[membrane-associated ring finger (C3HC4) 2] [21] . RNF24 has Golgi location and affects the intracellular trafficking of membrane proteins [22] . It is also possible that RNF121 regulates apoptosis through regulation of Golgi-related transport systems. This study instigates further investigation to the exact mechanism that RNF121 regulates apoptosis, especially to identify the molecules with which RNF121 interacts and the substrates of RNF121. This study also provides a potential target for cancer therapy, especially using RNF121 as a combined target with chemotherapy drug like VP-16.
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